🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “doxorubicin” Clear

  1. Anlotinib+ Liposomal Doxorubicin

    First Tracks Biotherapeutics

    Sarcoma

    phase 2 small molecule active

    1 trial

  2. BLEOMYCIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE , DACARBAZINE , PREDNISOLONE, VINCRISTINE , PREDNISONE, DOXORUBICIN

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  3. CYCLOPHOSPHAMIDE, PREDNISOLONE , Golcadomide, VINCRISTINE SULFATE, PEGFILGRASTIM, RITUXIMAB, Golcadomide, DOXORUBICIN, Golcadomide, VINCRISTINE SULFATE, RITUXIMAB, Golcadomide, PREDNISONE, BENDAMUSTINE HYDROCHLORIDE

    Celgene Europe Limited

    Newly Diagnosed Advanced Stage Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  4. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, DOXORUBICINA ACCORD HEALTHCARE ITALIA 2 mg/ml concentrato per soluzione per infusione

    Sana Biotechnology

    Pleural carcinosis

    phase 2 small molecule active

    1 trial

  6. DOXORUBICIN , CYCLOPHOSPHAMIDE , RITUXIMAB , POLATUZUMAB VEDOTIN , PREDNISONE , -, Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  7. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  8. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Cancer Prevention Pharma (Ireland) Limited

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  9. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  10. Doxorubicin liposome

    First Tracks Biotherapeutics

    Breast Cancer

    phase 2 small molecule active

    1 trial

  11. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai GmbH

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  12. Etoposide 20 mg/ml Concentrate for Solution for Infusion, Sodium Chloride 0.9% Intravenous Infusion BP, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Human Albumin Baxalta 50 g/l Solution for Infusion, Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion, Qarziba 4.5 mg/mL concentrate for solution for infusion, Dacarbazine Lipomed 200 mg powder for solu

    AXIM BIOTECHNOLOGIES, INC.

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  13. Liposomal doxorubicin hydrochloride

    Teva Pharma GmbH

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Rein Therapeutics

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)

    phase 2 small molecule active

    1 trial

  15. Myocet (Non-pegylated liposomal doxorubicin (NPLD))

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Cancer Prevention Pharma (Ireland) Limited

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  17. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Breast cancer

    phase 2 small molecule active

    1 trial

  18. Palifosfamide Tris and Doxorubicin

    Alaunos Therapeutics

    Soft Tissue Sarcoma

    phase 2 small molecule active

    1 trial

  19. RITUXIMAB , DOXORUBICIN , VINCRISTINE , IBRUTINIB , RITUXIMAB, PREDNISONE , CYCLOPHOSPHAMIDE

    Fondazione Telethon ETS

    Diffuse Large B-cell Lymphoma ABC

    phase 2 small molecule active

    1 trial

  20. RITUXIMAB, CYCLOPHOSPHAMIDE , AZD0486, PREDNISOLONE , VINCRISTINE , Calquence 100 mg film-coated tablets, RITUXIMAB , AZD0486, DOXORUBICIN , Calquence 100 mg film-coated tablets, PREDNISONE , AZD0486, AZD0486

    AstraZeneca AB

    Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  21. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  22. SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  23. VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, DOXORUBICIN HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE

    Ology Bioservices Ireland LTD

    Primary plasma cell leukemia

    phase 2 small molecule active

    1 trial

  24. VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB

    Genmab A/S

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources